Skip to main content

Menopausal Hot Flashes Market Size [2022-2029] | Industry Trends, Share, Growth, SWOT Analysis, Market Drivers, Restraints, Opportunities, And Key Developments

Menopausal Hot Flashes Market Covered By Key Companies – Pfizer Inc, Allergan, Teva Pharmaceutical Industries Ltd, Mylan N.V, Hisamitsu Pharmaceutical Co. Inc., GlaxoSmithKline plc, Novo Nordisk A/S

Pune, India, July 19, 2022 (GLOBE NEWSWIRE) — The surge in geriatric women population is expected to stimulate the growth of the market, states Fortune Business Insights, in a report, titled “Menopausal Hot Flashes Market Size, Share & Industry Analysis, By Treatment Type (Hormonal Treatment {Estrogen, Progesterone, Estrogen-progesterone Combination}, Non-hormonal Treatment, {Antidepressants, Others}, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026.” The growing awareness regarding women’s health is expected to spur lucrative business opportunities for the market.

The entire world is fighting with the highly contagious coronavirus, which has disrupted many industries across the globe. The authorities of several countries have initiated lockdown to prevent the spread of this deadly virus. Such plans have caused disturbances in the production and supply chain.


Request a Sample Copy of the Research Report:

https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/menopausal-hot-flashes-market-102816


Key Industry Development

April 2019: TherapeuticsMD, Inc. announced that it has introduced Bijuva (estradiol and progesterone) capsules for the treatment of moderate to severe hot flashes in menopause

Market Driver

Emergence of New treatments to Spur Business Opportunities

The growing prevalence of menopausal hot flashes is likely to encourage the healthy growth of the market during the forecast period. Hot flashes are one of the most common symptoms experienced by women during the time of menopause. According to an article published by the National Center for Biotechnology Information (NCBI), it is estimated that about 1.2 billion women worldwide will be menopausal or post-menopausal by the year 2030. The growing elderly women population is expected to favor the healthy growth of the market. The ongoing development of therapies and treatment by key players is predicted to enable the growth of the market.

For instance, in October 2017, Otsuka Pharmaceutical Co., Ltd., announced the launch of EQUELLE, a dietary supplement for the treatment of hot flashes during menopause. The increasing awareness about women’s health through initiatives by various public and private organizations is expected to create lucrative business opportunities for the market in the forthcoming years.  However, the side effects associated with hormonal products are expected to be a major factor in diminishing the growth of the market.


Click here to get the short-term and long-term impact of COVID-19 on this Market: https://www.fortunebusinessinsights.com/menopausal-hot-flashes-market-102816


Market Segmentation:

        

 

 

 

 

 

 

 

 

                                  Segmentation

By Treatment Type

  • Hormonal Treatment
    • Estrogen
    • Progesterone
    • Estrogen-progesterone Combination
  • Non-hormonal Treatment
    • Antidepressants
    • Others
  • Others
By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others
 By Geography

  • North America (USA, Canada)
  • Europe (UK, Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, Rest of Latin America)
  • Middle East & Africa (South Africa, GCC, and Rest of the Middle East & Africa)


Pre Book – Menopausal Hot Flashes Market:

https://www.fortunebusinessinsights.com/checkout-page/102816


Regional Analysis

Increasing Geriatric Women Population to Promote Growth in North America

The market in North America is expected to experience a rapid growth rate during the forecast period owing to the growing geriatric women population with menopausal symptoms in the US and Canada. The growing demand for medical assistance during hot flashes is expected to aid the expansion of the market. According to an article published by the National Center for Biotechnology Information (NCBI), it is estimated that about 85% of post-menopausal women have experienced menopause-related symptoms (hot flashes). Asia Pacific is expected to grow exponentially during the forecast period owing to the rising incidence of menopause in women. Europe is expected to dominate the market during the forecast period due to the development of innovative products by eminent players. The increasing partnership activities among industry players is predicted to foster healthy growth of the market in the region.  The surge in elderly women population is predicted to drive the global market in the forthcoming years.

The menopausal hot flashes market accentuates:

  • Comprehensive study of the market
  • Present and future forecast
  • In-depth data about key players
  • Latest industry trends and drivers

The Report Lists the Main Companies in the Menopausal Hot Flashes Market:

  • Pfizer Inc
  •  Allergan
  •  Teva Pharmaceutical Industries Ltd
  •  Mylan N.V
  • Hisamitsu Pharmaceutical Co. Inc.
  •  GlaxoSmithKline plc
  •  Novo Nordisk A/S


Have Any Query? Ask Our Experts:

https://www.fortunebusinessinsights.com/enquiry/queries/menopausal-hot-flashes-market-102816


About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

US: +1 424 253 0390

UK: +44 2071 939123

APAC: +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.